Compare SUIG & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUIG | ATRA |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.8M | 81.2M |
| IPO Year | 2022 | 2014 |
| Metric | SUIG | ATRA |
|---|---|---|
| Price | $1.03 | $9.20 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 2 | 2 |
| Target Price | ★ $5.75 | $5.00 |
| AVG Volume (30 Days) | ★ 522.4K | 39.9K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ N/A |
| Revenue | $3,898,631.00 | ★ $120,772,000.00 |
| Revenue This Year | $49.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.10 | N/A |
| 52 Week Low | $0.79 | $3.92 |
| 52 Week High | $6.88 | $19.15 |
| Indicator | SUIG | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 55.46 |
| Support Level | $0.81 | $9.28 |
| Resistance Level | $1.54 | $10.02 |
| Average True Range (ATR) | 0.10 | 0.52 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 50.00 | 76.02 |
Sui Group Holdings Ltd operates a treasury management business. It has established a publicly traded SUI treasury, backed by an exclusive relationship with the Sui Foundation, an independent organization dedicated to the advancement and adoption of the Sui network. The company executes its business by acquiring SUI tokens through open-market purchases, institutional-grade deal flow typically reserved for cryptocurrency funds, and a negotiated purchase agreement with the Sui Foundation. It is focused on capitalizing on technology trends and ecosystem growth relating to SUI, while providing liquid and institutional-grade access to blockchains. The company has one reportable segment, which is a digital asset platform focused on maximizing SUI per share value and advancing the Sui ecosystem.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.